The estimated Net Worth of Biotech Ap S Wg is at least $71.1 Million dollars as of 11 December 2023. Biotech Wg owns over 6,455 units of Y-Mabs Therapeutics Inc stock worth over $60,501,022 and over the last 5 years Biotech sold YMAB stock worth over $10,577,802.
Biotech has made over 10 trades of the Y-Mabs Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Biotech bought 6,455 units of YMAB stock worth $44,217 on 11 December 2023.
The largest trade Biotech's ever made was selling 150,000 units of Y-Mabs Therapeutics Inc stock on 8 June 2021 worth over $5,398,500. On average, Biotech trades about 61,888 units every 84 days since 2019. As of 11 December 2023 Biotech still owns at least 4,559,233 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Biotech Wg stock trades at the bottom of the page.
Biotech's mailing address filed with the SEC is RUNGSTED STRANDVEJ 113, , RUNGSTED KYST, G7, 2960.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, and Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: